Biotron Limited (BITRF) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Sydney, NSW, 호주. 현재 CEO는 Michelle Miller GCertAppFin.
BITRF 을(를) 보유 IPO 날짜 2013-03-22, 에 상장 Other OTC, 시가총액 $29.15M.
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
